Imaging biomarkers are poised to join biochemical and molecular markers as drivers of drug development and disease management. They enable researchers and clinicians to see into the body without invasive procedures. They frequently provide earlier detection of disease and its progression than molecular markers. Researchers use them to see in detail how their candidate drugs behave such as determining the percentage of target receptors occupied by a drug or observing a drug's ability to cross the blood/brain barrier. They promise to save time and money too.
Download this white paper in which experts analyze imaging biomarkers’ great promise and explore:

• Important trends in R&D and disease management
• Key technical and commercialization challenges
• Promising avenues for progress in the field- with examples of successful use of imaging biomarkers.

Although EDC brings tremendous efficiencies to clinical data collection, numerous repetitive clinical development activities exist beyond its scope which are in need of more efficient processes.  As these activities move from paper-based to electronic, the transition can be eased through the use of intelligent PDF forms.  Using XML capabilities, intelligent forms can follow workflows while leveraging established point solutions such as EDC, CTMS and IV/IWRS to optimize return on investment.
This White Paper describes:

• How intelligent PDF forms can accelerate repetitive clinical development processes, leading to faster development timelines
• How return on investment is maximized by being able to repeat time and cost savings across nearly all development phases and therapeutic areas

As a bio-technology or life sciences organization, your formulas, treatments and research and discoveries are the “lifeblood” of your business. But if you aren't protecting the integrity of your scientific data in your lab informatics systems, you risk losing IP ownership, revenue and consequently your business if you can't prove time-of-creation and data authenticity. Learn how you can implement simple, cost-effective and automated controls to protect your scientific intellectual property. Consider:

• IP protection requirements in bio-pharma and other science-oriented industries can extend out 20, 30, 40 or more years
• Most electronic lab management solutions include generic authenticity controls, so how "legally defensible" is yours?
• Only standards-compliant, independent controls can future-proof your approach to long-term IP integrity protection and authenticity.
• Learn more - get the free whitepaper now